Home
Search results “Best biotech etfs 2015”
What Investors Need to Know About Biotech ETF Investing
 
06:16
Despite concerns over a bubble and regulation, biotech investing remains very hot for investors. It doesn’t hurt that even with the recent sell-off the space is easily outperforming broad indexes so far in 2015. But with added risks, it might be time for investors to consider an ETF approach to the space so that one company doesn’t blow up a portfolio. Eric Dutram takes a look at the biotech ETF space and some of the key differences between the most popular funds in the space in this video. He also highlights a few factors that investors must consider when they are deciding which ETF is the best for their biotech investing needs. SPDR SP Biotech ETF: http://www.zacks.com/funds/etf/XBI/profile?cid=cs-youtube-ft-card iShares NASDAQ Biotechnology Index Fund: http://www.zacks.com/funds/etf/IBB/profile?cid=cs-youtube-ft-card Market Vectors Biotech ETF: http://www.zacks.com/funds/etf/BBH/profile?cid=cs-youtube-ft-card Bioshares Biotechnology Clinical Trials: http://www.zacks.com/funds/etf/BBC/profile?cid=cs-youtube-ft-card Bioshares Biotechnology Products Fund: http://www.zacks.com/funds/etf/BBP/profile?cid=cs-youtube-ft-card Follow us on StockTwits: http://stocktwits.com/ZacksResearch Follow us on Twitter: https://twitter.com/ZacksResearch Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Views: 1009 ZacksInvestmentNews
How to Invest in Leveraged Biotechnology ETFs
 
06:16
Yellen called biotechnology a bubble almost a year ago but the space has soared nearly 50% in the time frame. Eric Dutram takes a look at this volatile sector in more depth and discusses the many options to play the segment. This includes a host of leveraged and inverse options which look to especially be in focus as the ‘bubble’ in biotechnology grows.
Views: 766 ZacksInvestmentNews
How to Trade Biotech ETFs
 
26:32
Haven't done many videos on position trading. Here's on on biotech ETFs, XBI in particular, though this works with IBB, too. My Seeking Alpha Articles ► http://seekingalpha.com/author/damon-verial/articles ____________ Click Here To Subscribe! ► https://www.youtube.com/user/verial Website ► http://damonverial.com/ _________________________ Contact me at [email protected] ___________ https://youtu.be/33kIh6JxmVY
Views: 460 Damon Verial
Biotech ETF Surges | Trading Nation | CNBC
 
02:37
Larry McDonald, ACG Analytics, and Erin Gibbs, S&P Global, discuss the moves in the IBB biotech ETF with Brian Sullivan. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Biotech ETF Surges | Trading Nation | CNBC
Views: 264 CNBC
Biotechnology Investment $IBB 10 years
 
01:30
Biotechnology Stocks, as represented by the IBB ETF, have been in a strong uptrend and are off their highs. Is this climb sustainable?
Views: 143 Stocks Gowild
Biotech ETFs in Focus
 
55:43
Brad Loncar, Head of Loncar Investments, joins us in studio to spotlight the index behind the Loncar Cancer Immunotherapy ETF (CNCR) and discuss the innovation occurring in cancer treatment. Nate and Conor also explain why ETFs can be an excellent way to access the biotech space in general.
Views: 53 The ETF Store
Berger: Biotech ETFs bubbling higher
 
01:40
https://goo.gl/6I6Pr1 The massive rally in the biotechnology sector is not over according to Serge Berger, also known as The Steady Trader. Serge is interested in investing in the iShares Nasdaq Biotechnology ETF (IBB), which is up 20% year-to-date. Although the industry has seen tremendous growth, not all companies are seeing equal growth, which is why Serge is investing an ETF. The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF are the two largest ETFs in biotech. Given both the relative and absolute strength seen in the biotech sector over the past month, there is still potential for one more break higher according to Serge. Therefore, he is looking to buy the biotech ETF at USD 366.50 with a target of USD 385. A stop can be placed at USD 354. *Join the conversation below to be a part of the social trading experience. * _Non-independent investment research disclaimer_ (http://www.tradingfloor.com/about/niird) _Full disclaimer_ (http://www.tradingfloor.com/about/disclaimer)
Buying Your First Biotech Stock | Fool Co-Founder David Gardner Talks Healthcare | Part 2 of 8
 
04:44
View additional highlights from the interview: Part 1) Should Investors Fear Biotechs? https://www.youtube.com/watch?v=ZM16Rl58poc Part 2) Buying Your First Biotech Stock https://www.youtube.com/watch?v=pyNIKJCln84 Part 3) Why Everyone Should Own Stocks https://www.youtube.com/watch?v=DvPBvqDE1mg Part 4) Where to Find Great Stocks https://www.youtube.com/watch?v=UMnSYty_nxo Part 5) Always Invest the Same Way? https://www.youtube.com/watch?v=bnpu3cdiPg0 Part 6) Investors: How to Know the CEO https://www.youtube.com/watch?v=WrlQUNT4XKc Part 7) Amazon: Investing in a 100-Bagger https://www.youtube.com/watch?v=pdDQKApD-rc Part 8) Kickstarter: Upending Venture Cap? https://www.youtube.com/watch?v=xHrLtJY1D14 ------------------------------------------------------------------------ Investing made simple: The Motley Fool's essential guide to investing is now available to the public, free of cost, at http://bit.ly/1atRpHZ. This resource is truly all you need to get started today. To claim your free copy, simply click the link above -- no credit card required! Visit us on the web at http://www.fool.com, home to the world's greatest investing community. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool
Views: 3084 The Motley Fool
BIOTECH BANTER (Full Version)
 
16:33
Investing made simple: The Motley Fool's essential guide to investing is now available to the public, free of cost, at http://bit.ly/1atRpHZ. This resource was designed to cover everything that new investors need to know to get started today. For your free copy, just click the link above. Visit us on the web at http://www.fool.com, home to the world's greatest investing community! ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool
Views: 3617 The Motley Fool
How to Pick the Best Biotech Stocks on the Market, in Five Easy Steps
 
02:57
Use these simple steps to become a better biotech investor. These tips will help you pick the best biotech stocks to buy to improve returns and minimize risk. Learn how to… - Analyze the market capitalizations of biotech companies. - Find the average trading volume. - Analyze the beta. - Assess the short interest. - Read the Bollinger band. Apply these principles to pick the best biotech stocks on the market (right now and in the future). Plus you can learn how to take a look at our latest recommendation – a small biotech company we believe is poised to deliver 12 times the return on investment within two years: To view the transcript of our recommendation, click here: http://mney.co/1N3ySdE To watch the video of our recommendation, please click here: http://mney.co/1WiVbiu
Views: 3429 Money Morning
(IBB) Nasdaq Biotechnology ETF Market Chart Technical Analysis
 
11:00
Take an in depth look at the current chart for the IBB ETF
Views: 394 Mr. Stocks
ETF in Focus: iShares Nasdaq Biotech ETF (IBB)
 
02:12
ETF in Focus: iShares Nasdaq Biotech ETF (IBB) has seen large declines and new buying interest in 2014. We've ridden the waves in both directions.
Views: 178 ETF DIGEST
Biotech Sector Overview 7-22-16
 
40:30
An indepth look at the biotech sector via the etf XBI and the 10 largest components.
The Best Biotech Penny Stock Play Right Now
 
05:47
If you've read my book, download it here for free http://tim.ly/timsbook you know I had my first $100,000 profit day when I was just 19 on a over-the-weekend news play EXACTLY like this. I only have a small position here, but I think this stock can spike nicely on this predictable news
Views: 24373 Timothy Sykes
ETF ANALYST HOUR Q&A: Biotech Bull Market: How Long Can It Last?
 
02:32
Todd Rosenbluth answers additional questions from the S&P Capital IQ ETF Analyst Hour Webinar: Biotech Bull Market: How Long Can It Last? You can also learn more by clicking on this url: : http://bit.ly/18WZTfc and completing the registration form to access the replay of the webinar. Follow Todd Rosenbluth, S&P Capital IQ's Director of Mutual Fund & ETF Research, on Twitter @TRosen_SPCapIQ.
Biotech Collapse: This Chart Pattern Told Us To Short, 25K In Profits Made
 
04:48
Watch this live trading action video as Gareth Soloway details how the Pros traded iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) and more. When you are ready to step up your trading and investing game, enter the InTheMoneyStocks services and get all of the live trades now... 1) The Research Center is where swing traders & investors profit from the multiple day moves in the markets. View the Research Center track record of every single call for the past multiple years right here: http://bit.ly/SwingTradingTrackRecord (live/open calls are reserved for members). 2) Or if you are day trading the markets, enter our live trading room, the Intra Day Stock Chat, where the Pros day trade the market action live everyday during market hours... enter the room FOR FREE right here and start trading: http://bit.ly/LiveDayTrading 3) Options traders, no one can compete with this performance, your only smart move is to join them, check this out: http://bit.ly/OptionsTraders. Contact us with any questions: [email protected] When it comes down to FREE trading information, there is only one worthy source for you... our free stock market action emails will keep you on top of everything that you need to know, nothing you don't, sign up for free right here: http://bit.ly/FreeEmailAlerts.... If you ever read an email again, make sure it comes from where it matters!
Views: 418 InTheMoneyStocks
Pharma ETFs: A Better Healthcare Investment?
 
06:01
How have pharma ETFs held up during the biotech selloff?
Views: 530 ZacksInvestmentNews
Day Trading IBB Biotech ETF
 
16:03
Technical analysis biotech ETF morning email from prior night IBB
Views: 44 Eagle Trading
4 Stellar Stocks to Beat the Biotech Slump
 
03:50
The iShares Nasdaq Biotechnology ETF is down 13% thus far in 2016, but investors should not throw in the towel on biotech stars Amgen , Gilead , bluebird and Bellicum , said Brad Loncar, CEO of Loncar Investments. Shares of Amgen are up 5.4% thus far in 2016, but fell this week after its Phase III Clarion trial failed to meet its primary endpoint. The trial was testing Amgen's Kyprolis, a drug used to treat patients with relapsed or refractory multiple myeloma, which is a cancer of plasma cells. The drug didn't slow the regrowth of tumors better than rival cancer drug Velcade in combination with chemotherapy. "Everyone is waiting for Amgen to do a deal with the $35 billion in cash they have on hand," said Loncar. "And the Kyprolis trial failure stings, but not too much because it has been approved in other patient subsets already." Loncar Investments is behind the Loncar Cancer Immunotherapy ETF , which is down 8% thus far in 2016. Gilead shares have dropped 20% so far in 2016. The stock was hit this week after Leerink reduced its rating on the stock to "market perform" from "outperform." The firm lowered its price target to $94 from $112 on shares of the company, saying it is "outright bearish" on its Hepatitis C treatments. "Gilead's Hepatitis C business has matured, but the stock is still cheap," said Loncar. "And they have a war chest of $30 billion to do a transformative deal as well." Bluebird bio shares are up a healthy 16% year-to-date, but have soared 43% in the past month as the immunotherapy specialist is rumored to be a target for Japanese drug maker Takeda Pharmaceutical . Loncar said bluebird has been "laying low" this year and will soon unveil a slew of data at the upcoming ASH Conference (American Society of Hematology). Similarly, Loncar expects Bellicum Pharmaceuticals, another immunotherapy outfit, to have a lot to say at the ASH Conference. Bellicum has seen its shares recover to $20 from less than $8 this past March. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Healthcare, Biotech Remain Hot Says Rx Fund Manager Wruble
 
03:50
Healthcare and biotech stocks are very strong from a quantitative perspective while utilities are having problems powering ahead said Steven Wruble, portfolio manager for the Rx Premier Managers Fund. 'Our equities are showing momentum within the S&P 500. Utilities have probably the lowest momentum. Healthcare and biotech are very strong from a quant methodology,' said Wruble. 'And then from the global piece of this, which is half of the funds, equities are still in favor.' Wruble oversees the Rx Tactical Rotation fund which has returned just over 1% so far this year while being flat for the past 12 months. The fund owns sector ETFs within the S&P 500 Index. The main inputs to the fund’s sector model include price momentum, volume, volatility and the rate of change in volatility. As to why Wruble likes to use ETFs in this particular fund, he says it is because they provide 'an efficient mechanism to gain exposure.' Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Here's your trade on the Nasdaq Biotech ETF (IBB) (June 16, 2015) - Stock Market Mentor
 
02:19
Waiting for a good entry on a biotech stock? IBB is currently in a tight squeeze but if it breaks out I think this stock is going to continue its upward trend. If you’re interested in a more in-depth analysis I also recommend you become a member of Stock Market Mentor. You can read the full transcription of this video at the link below: http://stockmarketmentor.com/2015/06/do-you-see-this-squeeze-in-biotech-heres-your-trade-on-the-nasdaq-biotech-etf-ibb-june-16-2015-2/?utm_source=youtube&utm_medium=ytchannel&utm_campaign=cotd
Views: 114 Stock Market Mentor
The best biotech stock in the world?
 
08:47
The best biotech stock in the world?
Views: 324 Bill Gunderson
Biotech Stocks On Thin Ice
 
04:01
Biotechnology stocks as measured by the iShares Biotechnology ETF (IBB) have already corrected 40% off their 2015 highs but continue to look and feel heavy. An important technical support area is about to break. Watch today's VLOG for the trade setting up in biotechnology stocks. Follow me on Instagram: Instagram.com/steadytrader
Views: 629 Serge Berger
Time for investors to look into biotech?
 
04:35
JMP Securities President Mark Lehmann on the outlook for the biotech sector. Watch Dagen Mcdowell and Maria Bartiromo talk about Investing Basics and Stocks on Mornings With Maria.
Views: 211 Fox Business
Sector Investing with ETFs
 
02:47
Matt McCall takes a look at sector investing and shares the sectors he likes, such as regional banks and biotech, along with several of his favorite picks.
Views: 169 MoneyShow
Health Care Check Up: Prognosis Bullish
 
01:39
The health care sector has been the best performer in the S&P 500 index thus far in 2015 and yet S&P Capital IQ still has a number of favorable stock and ETF recommendations in the sector. In June, S&P Capital IQ hosted a Health Care Check Up: Prognosis Bullish live-streaming event for clients. During the event, Jeffrey Loo, head of health care equity research, pointed to a number of catalysts including demographics, health care reform, significant drug development and consolidation. He also highlighted the drivers he sees for the pharmaceutical and biotechnology industries, which are the two largest in the sector. Then Bob Dudley, Select Sector SPDRs Eastern Division Sales Manager, discussed how investors have been increasingly adding fresh money to health care sector and industry ETFs in 2015 and rotating away from the utilities sector. In the first five months of 2015, health care products added $6.7 billion of inflows. Todd Rosenbluth wrapped up the prepared remarks with a discussion of the S&P Capital IQ ETF philosophy and related research. Among the topics were the differences between market-cap weighted iShares and Market Vectors industry ETFs and the equally weighted SPDR peer products.
Biotechnology Stocks Are Ripe For A Sharp Bounce
 
04:21
After a historically strong rally in recent years, Biotechnology stocks and the Nasdaq Biotechnology Index ETF (IBB) finally exhausted themselves in 2015 and began to tumble. So far in 2016 biotechnology has been on a one-way street lower but for the near-term increasingly look to be oversold. Active investors and Traders could look to play a bounce. Watch the video to see the good reward to risk trade that is setting up in the IBB etf.
Views: 553 Serge Berger
Biotech Takeover: Successfully Identifying and Profiting from Biotech Buyout Targets
 
48:19
Owning a takeover target is one of the quickest ways to profits in the biotech sector. Biotech investing expert Bret Jensen will show you how to identify small and mid-size biotech companies with promising technologies that make them potential targets for acquisition from larger firms like Gilead, Amgen, Celgene and others. Bret will share with you the details of his process for screening potential takeover targets with a laser like focus. He'll also show you how to use his 4 criteria for any potential biotech takeover stock.
Views: 1110 MoneyShow
Berger: NASDAQ biotechnology sector overextended
 
01:48
http://goo.gl/rjgptV Serge Berger, who is also known as The Steady Trader, sees the potential for a large reversal in the NASDAQ Biotechnology ETF. The IBB index has seen impressive rallies over the past couple of years, gaining 30% in 2012, rallying 70% in 2013, and another 35% in 2014. Year-to-date the index is up 15%. Biotechnology stocks are extremely volatile according to Serge, and are susceptible to pullbacks ranging from 10-25%. With the IBB index currently extended above its 50 and 200 day moving averages, Serge believes there is potential for a 5-15% reversal. He is planning to short the index around USD 345 with a target of USD 320. A stop can be placed at USD 360. Join the conversation below to be a part of the social trading experience. _Non-independent investment research disclaimer_ (http://www.tradingfloor.com/about/niird) _Full disclaimer_ (http://www.tradingfloor.com/about/disclaimer)
Biotechs Still Inexpensive Despite Long Rally
 
02:32
The huge run-up in the price of biotech stocks in the past year has many investors – and even Fed Chair Janet Yellen – wondering if the rally has legs. Not to worry, said Todd Rosenbluth, Director of ETF & Mutual Fund Research at S&P CapitalIQ. 'We still have a lot of buy or strong buy recommendations on biotechnology companies,' said Rosenbluth. 'We think that the larger cap companies are still trading at a discounted PE multiple to the broader market and to the healthcare sector and they also have stronger catalysts.' Biotechnology was the best performing sub-industry, up 289% from 2011to 2014, ahead of the S&P Health Care Sector and the broader S&P 1500 indices gains of 118% and 64%, respectively. Nearly a year ago, Yellen famously warned of 'substantially stretched' valuations in biotech, as well as social media stocks. In terms of valuation, Rosenbluth pointed out that biotech is not expensive relative to the broader market. He cited that the S&P 1500 Biotechnology Industry trades at forward P/Es of 18.2X (2015) and 15.2X (2016), well below the health care sector's 19.3X and 16.5X and the broader S&P 1500 index's multiples of 18.4X and 15.9X. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Healthcare ETFs for Long Term Investors
 
05:31
Healthcare ETFs have been beating the broader markets over the last couple of years and the outlook still remains positive (VHT, XLV).
Views: 2060 ZacksInvestmentNews
Can Biotech Stocks Keep Rallying?
 
04:18
It has been a steep and relentless ascent for most parts of the US equity market since the January/February lows. Some market pundits are now calling for biotechnology stocks (IBB etf) to become the next market leader. While I don't think biotech stocks have to fall apart here, they do look very stretched for the time being. Watch the Free video for the trade setup in the biotechnology ETF (IBB).
Views: 562 Serge Berger
ETF IBB NASDQ BIO TECH INDEX NYSE BIOTECH BTX.X THE BIG GAINERS FOR THE YEAR
 
08:50
http://www.StockMarketFunding.com ETF IBB NASDQ BIO TECH INDEX NYSE BIOTECH BTX.X THE BIG GAINERS FOR THE YEAR (VIDEO). Learn how to profit in 2014 & 2015 trading biotechnology stocks through the biotech ETF IBB. We'll cover everything you need to know in this live 2 part series. Free Trial Signup http://www.stockmarketfunding.com/Free-Trading-Seminar Follow us on Facebook: http://www.facebook.com/OnlineTradingPlatform Follow us on Twitter https://twitter.com/TradeEducation Find Us on Google +1 http://gplus.to/TradingStocks Join us on Linkedin http://www.linkedin.com/groups/StockMarketFunding-Pro-Traders-1143227 Email Signup http://www.stockmarketfunding.com/evideosignup.htm Tags "stock market news" "stock market" "stock market data" "stock market report" "stock markets" "stock markets" "stock market today" "nasdaq stock market" "stock market quotes" "world stock market" "stock market ticker" "stock market index" "stock market watch" "stock market cycles" "stock market charts" "stock market results" "stock market software" "stock market hours" "stock market trends" "stock market prices" "stock market analysis" "us stock market" "live stock market" "stock market" "high frequency trading" "technical analysis" "hft trading" "option trading" "options trading" "stock market tutorial" "stock market technical analysis" "how to trade options" "how to trade stocks" "stock market funding" stockmarketfunding.com "Options Trading Strategies" "Options Trading" "Stock Chart Technical Analysis" "Stock Technical Analysis" "Options Trading Education Video " "Stock Market Trading" "Stock Market Trading Education" "Stock Market Trading Account" "Stock Market Trading Education" "Stock Options Trading" "Stock Options Trading Education" "Stock Market" "Stock Trading" "Online Trading" "Day Trading" "Swing Trading" "Technical Analysis" "Stock Trade" "Options Trade" Investing Trader Market Markets Invest Investment "US Stocks" "Stock Market Trade" "High Frequency Trading"
Cramer: Invest in Biotech
 
03:13
Cramer: Invest in Biotech
Best Buys for a Biotech Bubble | 3/25/14 | The Motley Fool
 
05:16
Investing made simple: The Motley Fool's essential guide to investing is now available to the public, free of cost, at http://bit.ly/1atRpHZ. This resource was designed to cover everything that new investors need to know to get started today. For your free copy, just click the link above. ------------------------------------------------------------------------ There has been a lot of buzz in recent days about the idea of a bubble in the biotech space on the market today. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB), an ETF that tracks a range of companies in the biotech space, peaked exactly a month ago, and has since lost 12% of its value, falling 3% in a single day yesterday. Investors are understandably concerned that the sell-off will lead to a continued decline in the days ahead. In this video, Motley Fool healthcare analyst David Williamson discusses why there may be some validity to the speculation of a bubble in this sector at the moment. David then gives investors his three top picks for which companies he would jump in on if a biotech pullback offered a lower price point, and why these three pharmaceutical businesses have the underlying strength to survive any market condition. Visit us on the web at http://www.fool.com, home to the world's greatest investing community! ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool
Views: 3235 The Motley Fool
3 Biotech Stocks The Top Fund of 2015 Thinks Investors Should Own Now
 
02:43
Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreli, provides an interesting investment opportunity, according to one portfolio manager with an expertise in biotech investing. Michael Tung is co-portfolio manager of Turner Medical Sciences Long/Short Fund, which was the top ranked long/short fund in 2015 according to Morningstar, with a return of nearly 18 percent. Shkreli, you may recall, was indicted on a scheme to defraud Retrophin, a company he founded and previously served as CEO. Despite the legal drama, Tung said there is not a lot of risk in owing the stock. ‘The management team there is excellent,’ said Tung. ‘It’s a very interesting company in that they have several orphan assets, orphan drugs. In addition, right now they also have over $250-million in cash.’ Tung said the company is looking to make acquisitions, and will benefit from the decline in market valuations of potential biotech targets. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
MaRS Best Practices - Special Valuation Series: Valuations in the biotech industry
 
01:20:38
Canada's biotechnology and cleantech communities have a history of developing world-leading technologies and a reputation for producing some of the best research minds in the world—but for these industries to grow, they must have access to new capital to fund research and development that will allow Canada to maintain its position as a world leader. The problem of a lack of capital is compounded by ever-increasing expectations from investors as to what they expect to see from companies before they consider an investment. Part of the MaRS Best Practices Series MaRS - Building Canada's next generation of global technology companies. marsdd.com
Vanguard Health Care ETF Not Showing Signs of Slowdown
 
02:12
The Vanguard Health Care ETF (VHT) will continue its terrific run because it employs a healthy mix of big-cap pharma and biotech, said Paul Frank, Portfolio Manager for Stadion Money Management. Frank added that Stadion ranks over 1300 ETFs every day for their risk adjusted returns and the VHT continues to be among the top performers. He said the iShares Core S&P Mid-Cap (IJH) also ranks highly because it compensates holders for the volatility they are taking on. Finally, Frank is a fan of the Vanguard Total International Bond ETF (BNDX), saying the steady returns it has provided in the past year are not in danger. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Biotech Wreck Part 2
 
31:07
A detailed look at the near-term & longer-term outlook for the biotech sector, including XBI, IBB, PBE and several of the top biotech stocks.
Biotech Stocks Etf | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks
 
13:55
http://tinyurl.com/biotechmillionaire ◄ CLICK HERE To Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks! Tags biotech sector etf biotech etf stock price best biotech stocks etf biotech stock index etf small cap biotech stocks etf biotech stocks etf etf for biotech stocks
Biotech Stocks Are On Fire As Obamacare Repeal Vote Looms | CNBC
 
00:54
The SPDR S&P Biotech ETF (XBI) climbed more than 3 percent on Wednesday, putting it on track to post its best weekly performance since March 13. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Biotech Stocks Are On Fire As Obamacare Repeal Vote Looms | CNBC
Views: 444 CNBC
Total Return Analysis of the Top Biotech ETF (IBB)
 
03:50
https://goo.gl/QPCkqk - Start earning with binary options like millions of traders do For investors who find the biotech industry intriguing and want to secure a means for diversified investments within biotech that avoid the risk of simply selecting a single company while also avoiding the intensive due diligence required to manual diversify should consider a biotech-focused ETF like the IBB. The largest US-traded biotech ETF is IBB. As of Sep. 06, 2016, it has total assets of around $7,446 million. IBB is overseen by BlackRock Fund Advisors and comes with an expense ratio of .48%. The fund was issued on Feb. 09, 2001. Its primary benchmark is the NASDAQ Biotechnology Index and IBB focuses its assets on firms performing biomedical research in hopes to discover and/or develop innovative treatments and new cures for diseases that threaten humanity. The fund’s liquidity is high, which makes it an easy option for investors to increase positions as well as exit. One caveat: the fund only trades in NASDAQ-listed stocks. This means it does not provide access to a significant subsector within the biotech market that includes a number of potentially strong biotech startups that are traded on the NYSE. Nevertheless, this is a solid fund weighted in favor of larger-cap companies that has proven to be a valuable vehicle for many investors building wealth through long-term investments in biotech. (For more, see: Top 3 Biotech ETFs.) Total Returns Since Inception According to BlackRock, as of Aug. 31, 2016, IBB features an average annual total return of 7.00% (represents changes to the NAV) since its inception in February 2001. Over the past ten years, IBB exhibits an average annual total return of 14.51% and over the past five years of 24.10%. In particular, over the last six years (2010 until 2015), the ETF has performed highly positive: Performance 2010 14.83% Performance 201 11.72% Performance 2012 32.13% Performance 2013 65.54% Performance 2014 33.83% Performance 2015 11.56% After such a positive performance run over the past six years, the current year-to-date total return in 2016 is negative at -15.93%, as of Sep. 06, 2016. The Bottom Line A highly liquid exchange-traded fund option for investors who seek to increase exposure to US biotechnology stocks. Of course, prior to a final decision on investing, the proper due diligence and risk tolerance assessments that all investors should undertake must be performed with the IBB ETF.
Views: 8 ETFs
Three Biotech Companies to Add to Your Portfolio Right Now
 
01:24
Driven by the demand for effective treatments and new cures, biotech is one of the hottest investment areas today. There has even been speculation of a biotech bubble. The sector has been growing at an annual rate of 9% since 1997, well above the overall economy. The U.S. dominates the Biotech industry both in terms of number of firms with nearly 7,000 - and R&D spending with $26 billion in 2014. Here are some of the best biotech companies TheStreet Quant Ratings says you should consider looking at. Number 3 is Biogen. With an 'A-' rating, the company's strengths can be seen in its revenue growth and notable return on equity.2nd is, Gilead Sciences. This rating is an 'A.' Gilead thrives in its growth in earnings per share and compelling growth in net income. Number 1 is Amgen. With an 'A+' rating the company flourishes in its revenue growth and compelling growth in net income. TheStreet Ratings are algorithmic stock picks based on 32 major data points. S&P 500 stocks rated 'buy' yielded a 16-and-a-half-percent return in 2014, beating the S&P 500 Total Return Index by more than 300 basis points. For the full reports on these stocks, you can check out TheStreet.com/QuantRatings. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
How to Perform Serious Sector Analysis Using ETFs
 
07:20
In today's video, I'll be examining nine different sectors of the economy and analyzing their trends using SPDR ETFs. Out of the nine different sectors, I'll be looking at three of these sectors with strong uptrends, while the remaining six sectors are in a transition stage. I will, of course, be applying the Trade Triangle technology to each of these nine sectors so you can clearly see how to put each of these sectors to work you. Creating an ETF sector portfolio is easy and is not as difficult as you may imagine. The first thing you need to do is create a separate portfolio in your Portfolio Manager and enter these nine ETF symbols. Energy Select Sector SPDR ETF (PACF:XLE) Financial Select Sector SPDR ETF (PACF:XLF) Health Care Select Sector SPDR ETF (PACF:XLV) Industrial Select Sector SPDR ETF (PACF:XLI) Materials Select Sector SPDR ETF (PACF:XLB) Consumer Discretionary Sector SPDR ETF (PACF:XLY) Consumers Staples Select Sector SPDR ETF (PACF:XLP) Tech Select Sector SPDR ETF (PACF:XLK) Utility Select Sector SPDR ETF (PACF:XLU) Once you get all these symbols into your portfolio, you can name it, "Sector ETF Portfolio" or any other name you choose. There are advantages and disadvantages using ETFs, take for example XLK in the Tech sector. The advantage is that you have an ETF that invests in a broad spectrum of tech stocks. This gives you a way to invest without having to invest in each of the individual stocks contained in the ETF. The disadvantage is that an ETF is not going to perform as well as the individual stock. Because of its diversified structure, an ETF will only reflect the general trend of a sector.
Views: 1186 MarketClub
2015 Biotech Stock List
 
01:21
Visit this site http://bestpennystocks.org/biotech-stocks/ for more information on 2015 Biotech Stock List. Biotech stocks are often included in every 2015 Biotech Stock List because they have shown to be very profitable investments. We have compiled a list of the best biotech penny stocks to watch for in 2015.
Views: 117 Cassandra Nelson
Best & Worst ETFs & Mutual Funds: Health Care Sector
 
04:09
The Health Care sector ranks sixth out of ten in our Sector Rankings for ETFs and Mutual Funds. For the fully optimized version of this clip, please navigate to http://reut.rs/1q2hLyn
Views: 119 New Constructs
PillPack Review: Top Hottest Biotech Startups Ranking - AngelKings.com
 
05:59
PillPack Review, and top biotech startups (http://angelkings.com/biotech-startups). Review of PillPack's product, CEO TJ Parker, includes what to look for when investing in biotech stocks and startups. Angel investing and startup expert, Ross Blankenship (http://angelkings.com/course) discusses PillPack's team and product as delivering important medicines. What are the top biotech companies like PillPack? Want to get information on angel investing and venture capital in biotechnology companies? If you'd like to learn about startup investing or want to see if you're an accredited investor apply at http://angelkings.com/invest. Angel Kings are the angel investing and venture capital experts. You can invest by visiting AngelKings.com and learning about top biotech startups. The first investors in PillPack were Accel Partners, Atlas Venture, CRV, Founder Collective, Menlo Ventures, and Sherpa Ventures. #PillPack #Biotech #Startups #Ranking #Biotechnology
How to Buy Great Healthcare Stocks - Industry Focus
 
21:35
Investing made simple: The Motley Fool's essential guide to investing is now available to the public, free of cost, at http://bit.ly/1pCQeNI. This resource was designed to cover everything that new investors need to know to get started today. For your free copy, just click the link above. Visit us on the web at http://www.fool.com, home to the world's greatest investing community! ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool
Views: 2283 The Motley Fool
Market Vectors Biotech ETF
 
02:06
VIDEO FINANCIAL REPORTING Why Invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances. Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein. DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements. EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness. FINANCIAL DATA. Historical and fundamental data, ratios, exchange rate, prices and estimates are provided by Xignite,www.xignite.com. Data are sourced by Morningstar research. Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein. Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade. COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner . Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article. If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email: [email protected]
Views: 12 Why Invest In